We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 40

Dietary Supplement & Cosmetics Legal Bulletin: November 2016
  • Shook Hardy & Bacon LLP
  • Canada, USA
  • November 30 2016

The Federal Trade Commission (FTC) has secured orders against 29 defendants whom it claims deceptively marketed and billed consumers for skin care


Moneytree report shows increased life sciences investments in Q1 2011
  • Shook Hardy & Bacon LLP
  • USA
  • May 19 2011

According to a PricewaterhouseCoopers report on venture capital investments, although fewer deals occurred in the first quarter of 2011 (Q1 2011) as compared to the last quarter of 2010, investment activity increased 5 percent overall


Venture capitalists are returning to life-sciences investing
  • Shook Hardy & Bacon LLP
  • USA
  • October 3 2012

Reuters reports that a number of global venture firms have renewed their interest in the life sciences and health-care sectors, motivated by big acquisitions, U.S. laws speeding up certain drug approval processes and new products that have broadened the life-sciences definition


New program to provide accelerated “speed-to-market” for medical device entrepreneurs
  • Shook Hardy & Bacon LLP
  • USA
  • March 1 2012

The nonprofit Memphis Bioworks Foundation and Innova, a pre-seed, seed and early-stage investor, have announced a program designed to help entrepreneurs bring medical device products and companies to market


MEI Pharma secures $27.5 million in commitments to develop cancer therapy
  • Shook Hardy & Bacon LLP
  • USA
  • November 15 2012

According to a news source, San Diego-based oncology company MEI Pharma, Inc. is set to raise $27.5 million from commitments to purchase its stock and warrants in a private placement


NASDAQ Biotechnology Index surpasses all-time high in 1Q13
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe


Corporate venture funding for funding surges
  • Shook Hardy & Bacon LLP
  • USA
  • August 7 2014

Silicon Valley Bank (SVB) has issued a report that explores health-care and biotech investments and exits based on 2013 data and concludes, "Large


Biotech investments rise in Q4 2012, but remain off for the year
  • Shook Hardy & Bacon LLP
  • USA
  • January 24 2013

Pricewatershouse Coopers LLP has released its fourth quarter (Q4) and final 2012 venture capital investment reports and notes that "Biotechnology


Royalty financing gains favor for VC biotech funding
  • Shook Hardy & Bacon LLP
  • USA
  • August 29 2013

According to a former venture capitalist (VC), a recent deal involving a royalty in exchange for a cash infusion to develop and commercialize a


Biotech IPO boom continues
  • Shook Hardy & Bacon LLP
  • USA
  • August 1 2013

According to Xconomy's National Biotech Editor Luke Timmerman, the 24 biotech initial public offerings (IPOs) in 2013 are double those normally seen